Lourenco MC, Reis RS, Ferreira RM, Neves IJ, Rolla VC, Passos SR, Fonseca LS; IAS Conference on HIV Pathogenesis and Treatment (2nd : 2003 : Paris, France).
Antivir Ther. 2003; 8 (Suppl.1): abstract no. 877.
Evandro Chagas Clinical Research Institute in Rio de Janeiro-Brazil
Rationale: The endemic condition of tuberculosis, the co-morbidity with HIV and MDR strains became very important issues in clinical treatment, and continuos monitoring of drug resistance should be performed. The Instituto de Pesquisa Clinica Evandro Chagas (IPEC) is a Fiocruz unit specializes in infectious diseases and the bacteriology laboratory is a tuberculosis diagnosis reference centre for the State Department of Health of Rio de Janeiro. OBJECTIVE: Describe the frequency of TB-MDR strains from 1990 to 2000. METHOD: We tested the susceptibility of 364 clinical isolates of MTB assisted in IPEC (1990-2000) with confirmed diagnosis of tuberculosis. The tests were performed following Canetti et al., 1963. Tested drugs were rifampin (40 microg/ml), isoniazid (0.2 microg/ml), pirazinamide (100 microg/ml), streptomycin (4 microg/ml), ethambutol (2 microg/ml) and ethionamide (20 microg/ml). RESULTS: We found 44 patients (12.1%) with some kind of resistance and 10 patients showed MDR strains (2.7%). The average of resistance was 4.1 % and the mode was 3.0. The results distribution were similar during the study years chi2=4.9 (P=0.29). CONCLUSION: We found no relevant increase in MTB resistance during the 90s. This kind of simple study can contribute to epidemiological surveillance of MDR-TB.
Publication Types:
Keywords:
- Biomedical Research
- Brazil
- Chagas Disease
- Ethambutol
- Ethionamide
- HIV Seropositivity
- Humans
- Isoniazid
- Mycobacterium tuberculosis
- Rifampin
- Streptomycin
- Tuberculosis
- epidemiology
- psychology
Other ID:
UI: 102263155
From Meeting Abstracts